CVS Group (CVSG)

Sector:

Retailers

Index:

FTSE AIM 50

1,072.00p
   
  • Change Today:
      6.00p
  • 52 Week High: 2,188.00p
  • 52 Week Low: 922.00p
  • Currency: UK Pounds
  • Shares Issued: 71.72m
  • Volume: 526,970
  • Market Cap: £768.85m
  • RiskGrade: 136

Berenberg reiterates 'Buy' on CVS Group, hails margin expansion

By Alexander Bueso

Date: Friday 31 Mar 2017

LONDON (ShareCast) - (ShareCast News) - Analysts at Berenberg hailed CVS Group's shift in its business mix, with the resulting margin expansion that resulted, reiterating their 'Buy' recommendation on the stock in the process.


However, like-for-like sales were likely to slow towards the sector average in second half of the year, the broker cautioned.

Even so, the broker raised its earnings per share forecasts for 2017 to 2019 by 4.0% for each year, as a result of which it bumped up its target from 1,200p to 1,220p.

Although investors often focus on the rate of growth in like-for-like sales and M&A when analysing the veterinary group, the most noteworthy aspect of the firm's interims was its improved operating margin at the operating level, it said.

In terms of earnings before interest, taxes, depreciation and amortisation, margins rose to 16.1% from 14.5% in the previous six-month stretch, even as CVS invested significantly on people and equipment.

The key to the fatter margins was nevertheless the "strong improvement" in profitability in the vet practice side of the business, as CVS shifted towards higher-margin services versus drugs even as it moved to use more of its own brand drugs, with the latter having their own benefits.

"We have increased our forecast margins for the business as we believe the business will continue to benefit as the volume of own brand drugs sold in the business continues to grow," Berenberg said.

Analyst Sam England also pointed out that the company's M&A continued to be highly accretive even though in the latest six months it had paid an average price of 7.5 times historical EBITDA, instead of the seven times operating profits seen in fiscal year 2016.

That contributed to England's decision to lift his estimates.

CVS still had between £30.0m to £40.0m of firepower for M&A left, assuming it leveraged up the business to 2.5 times profits, he said.

On a slightly more cautious note, England tipped his hat to the company's "exceptionally strong" 7.2% increase in LFL in the first half of 2017 but added that a level of growth closer to the UK veterinary market's average rate of between 3% to 4% was more likely in the second half.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

CVS Group Market Data

Currency UK Pounds
Share Price 1,072.00p
Change Today 6.00p
% Change 0.56 %
52 Week High 2,188.00p
52 Week Low 922.00p
Volume 526,970
Shares Issued 71.72m
Market Cap £768.85m
RiskGrade 136

CVS Group Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
81.37% below the market average81.37% below the market average81.37% below the market average81.37% below the market average81.37% below the market average
74.36% below the sector average74.36% below the sector average74.36% below the sector average74.36% below the sector average74.36% below the sector average
Price Trend
71.59% below the market average71.59% below the market average71.59% below the market average71.59% below the market average71.59% below the market average
89.74% below the sector average89.74% below the sector average89.74% below the sector average89.74% below the sector average89.74% below the sector average
Income
94.47% below the market average94.47% below the market average94.47% below the market average94.47% below the market average94.47% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
46.78% above the market average46.78% above the market average46.78% above the market average46.78% above the market average46.78% above the market average
70.00% above the sector average70.00% above the sector average70.00% above the sector average70.00% above the sector average70.00% above the sector average

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 2
Sell 1
Strong Sell 0
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CVS Group Dividends

  Latest Previous
  Final Final
Ex-Div 02-Nov-23 17-Nov-22
Paid 08-Dec-23 02-Dec-22
Amount 7.50p 7.00p

Trades for 29-May-2024

Time Volume / Share Price
16:35 39,796 @ 1,072.00p
16:35 300 @ 1,072.00p
16:35 345 @ 1,072.00p
16:35 371 @ 1,072.00p
16:35 88 @ 1,072.00p

CVS Group Key Personnel

CEO Richard Fairman
Finance Director Robin Alfonso

Top of Page